These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson's Disease: A Systematic Review. Ebada MA; Alkanj S; Ebada M; Abdelkarim AH; Diab A; Aziz MAE; Soliman AM; Fayed N; Bahbah EI; Negida A CNS Neurol Disord Drug Targets; 2019; 18(4):317-325. PubMed ID: 30868968 [TBL] [Abstract][Full Text] [Related]
11. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Trenkwalder C; Berg D; Rascol O; Eggert K; Ceballos-Baumann A; Corvol JC; Storch A; Zhang L; Azulay JP; Broussolle E; Defebvre L; Geny C; Gostkowski M; Stocchi F; Tranchant C; Derkinderen P; Durif F; Espay AJ; Feigin A; Houeto JL; Schwarz J; Di Paolo T; Feuerbach D; Hockey HU; Jaeger J; Jakab A; Johns D; Linazasoro G; Maruff P; Rozenberg I; Sovago J; Weiss M; Gomez-Mancilla B Mov Disord; 2016 Jul; 31(7):1049-54. PubMed ID: 26990766 [TBL] [Abstract][Full Text] [Related]
12. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Tison F; Keywood C; Wakefield M; Durif F; Corvol JC; Eggert K; Lew M; Isaacson S; Bezard E; Poli SM; Goetz CG; Trenkwalder C; Rascol O Mov Disord; 2016 Sep; 31(9):1373-80. PubMed ID: 27214664 [TBL] [Abstract][Full Text] [Related]
13. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788 [TBL] [Abstract][Full Text] [Related]
14. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135 [TBL] [Abstract][Full Text] [Related]
16. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. Wong KK; Alty JE; Goy AG; Raghav S; Reutens DC; Kempster PA Mov Disord; 2011 Jul; 26(8):1552-5. PubMed ID: 21538524 [TBL] [Abstract][Full Text] [Related]
18. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. Hauser RA; Pahwa R; Tanner CM; Oertel W; Isaacson SH; Johnson R; Felt L; Stempien MJ J Parkinsons Dis; 2017; 7(3):511-522. PubMed ID: 28777755 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C; Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606 [TBL] [Abstract][Full Text] [Related]